LLLeith León-Maldonado

Leith León-Maldonado

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Leith León-Maldonado has a total of 158 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Extended HPV typing as an efficient alternative within HPV ‐based screening programs

    by Joacim Meneses‐León, Berenice Rivera‐Paredez, Sonia Hernández‐Salazar, Leticia Torres‐Ibarra, Martha Carnalla, Leith León‐Maldonado, Rubí Hernández‐López, José Damián Cadena‐Fiscal, Anna B. Moscicki, Manuel Quiterio‐Trenado, et al.

    Extended high‐risk human papilloma virus (hrHPV) typing emerges as a potential alternative for detecting cervical intraepithelial neoplasia 3 (CIN3), without additional triage tests. We evaluate the extended hrHPV typing as an alternative to improve CIN3 detection within an HPV‐based screening program. Between January 2017 and August 2018, 5856 women aged 25–65 years were screened as part of a public cervical cancer screening program of the Tlalpan Sanitary Jurisdiction in Mexico City. HPV testing was performed by BD Onclarity™, which individually detects hrHPV types 16, 18, 31, 45, 51, and 52, and pools of types 33/58, 56/59/66, and 35/39/68. Specific hrHPV types within these pools were further identified using the Atila AmpFire platform. All HPV‐positive women ( n = 691) were referred to colposcopy evaluation for diagnostic confirmation. Of these, 561 women completed both colposcopy and histological confirmation, representing our analytical sample. HPV‐16 alone had a sensitivity of 43.0% and specificity of 85.4% for CIN3 detection. Sequentially adding HPV‐18/33/31/39 increased sensitivity to 100% for CIN3 detection, although with lower specificity (54.5%). The proportion of HPV‐16/18/33/31/39 positive women was 47.0%, with a CIN3 PPV 5.3%. Extended genotyping with HPV‐16/18/33/31/39 achieved 100% sensitivity for CIN3 detection, but a moderate specificity. This strategy aligns with the international recommendation for colposcopy referral in women with a PPV of CIN3 larger than 4.0%.

  • Open Access

    Barriers and facilitators to a combined strategy of HPV vaccination and cervical cancer screening among Mexican women

    by Leith León-Maldonado, Alejandra Cabral, Gabriela Pages, Brandon Brown, Betania Allen-Leigh, Eduardo Lazcano-Ponce, Francesc Xavier Bosch, Donna Spiegelman, Leticia Torres-Ibarra, Raúl U. Hernández-Ramírez, et al.

    HPV-FASTER is an innovative public health intervention combining HPV vaccination and HPV-based screening in adult women at the same visit. FASTER-Tlalpan adapted the combined HPV-FASTER strategy in Tlalpan, Mexico City for women aged 25-45 years. To understand the barriers and facilitators to participation in a combined strategy, we conducted semi-structured interviews with 14 FASTER-Tlalpan participants. We used the constant comparative method for the analysis, as well as the socioecological model to organize the findings. At the intrapersonal level, barriers included the belief that only younger women are at risk for HPV, embarrassment about the pelvic exam, and lack of time, while facilitators were having information regarding the benefit of the combined strategy, perception of time saved by having both procedures at once, feeling reassured about their health, self-esteem regarding their health, and perceived severity of cervical cancer. Interpersonal-level barriers were experiences of stigma and prejudice, and lack of support from partners, while facilitators were family encouragement and peer-to-peer communications. Institutional-level barriers were lack of infrastructure and inconvenient hours at the health center, perceived high time burden, and low quality of care from providers, while facilitators included high-quality care by health center personnel, including partners in the combined strategy, and phone reminders. Community-level facilitators included willingness to participate. Public policy facilitators included mass information campaigns and free procedures. Our findings point to significant barriers which need to be addressed, along with facilitators which can be leveraged to scale up the combined strategy in similar settings.


  • Open Access

    Tamizaje del cáncer cervical

    by Leith Soledad León-Maldonado, Nancy López-Olmedo, Raúl Murillo, Erika Hurtado-Salgado, Betania Allen-Leigh, Alejandra Armengol-Alonso, Gabriela Torres-Mejía, Sergio Bautista-Arredondo, Tonatiuh Barrientos-Gutiérrez, Eduardo Lazcano-Ponce

    Objetivo. Estimar las prevalencias de uso de las pruebas del Papanicolaou (Pap) y del virus del papiloma humano (VPH) antes y después del inicio de la pandemia por SARS-CoV-2. Material y métodos. Se analizó el uso de las pruebas de tamizaje Pap y/o VPH en mujeres de 25 a 64 años (población objetivo) utilizando datos de Encuestas Nacionales de Salud y Nutrición 2018 y 2021-2023. Resultados. El uso de Pap disminuyó de 34.6% en 2018 a 24.9% en 2021, recuperándose hasta alcanzar 31.5% en 2023. De forma similar, el uso del VPH disminuyó de 12.7% en 2018 a 11% en 2021, y se incrementó a 16.0% en 2023. Se observó un mayor uso de las pruebas de detección del cáncer cervical a mayor nivel socioeconómico y urbanización. Conclusiones. Es preciso actualizar las directrices normativas y revisar los lineamientos para facilitar el tamizaje y el seguimiento del cáncer cervical en México.


  • Open Access

    Data from Clinical Performance of hrHPV Primary Screening Using Vaginal versus Cervical Samples to Detect High-grade Intraepithelial Lesions

    by Jonathan King, Yvonne N. Flores, Joacim Meneses-León, Sonia Hernández-Salazar, Karina Robles-Rivera, Berenice Rivera-Paredez, Leith León-Maldonado, Rubí Hernández-López, Leticia Torres-Ibarra, Eduardo Lazcano-Ponce, et al.

    High-risk human papillomavirus (hrHPV) testing is now the most recommended primary method for cervical cancer screening worldwide. Clinician-collected cervical sampling continues to be the main sampling method, but hrHPV vaginal self-sampling is an appealing alternative because of its greater acceptability and potentially higher cost-effectiveness. This study aimed to determine whether hrHPV vaginal self-sampling is comparable with clinician-collected cervical sampling for detecting histologically confirmed high-grade cervical intraepithelial neoplasia (CIN2/3) as part of a cervical cancer screening program in Mexico. We analyzed data from 5,856 women screened during a hrHPV-based screening study. Clinical performance and diagnostic efficiency metrics were estimated for the two sampling methods for the CIN3 and CIN2+ endpoints, using three triage strategies: HPV16/18 genotyping, HPV16/18/33/58 extended genotyping, and HPV16/18/31/33/58 extended genotyping. hrHPV-positivity was found in 801 (13.7%) cervical and 897 (15.3%) vaginal samples. All women with hrHPV-positive samples were referred to colposcopy, which detected 17 total CIN3 cases before considering retrospective triage strategies. Using the HPV16/18/31/33/58 extended genotyping strategy, 245 women had hrHPV-positive cervical samples and 269 had hrHPV-positive vaginal samples. Ten CIN3 cases were detected each among women with hrHPV-positive cervical samples and among those with hrHPV-positive vaginal samples when using this strategy, with no significant differences in sensitivity and specificity observed. We observe that self- and clinician-collected sampling methods are comparable for detecting CIN3 and CIN2+ regardless of the triage strategy used. These findings can help public health officials to develop more cost-effective cervical cancer screening programs that maximize participation.Prevention Relevance:We found that hrHPV vaginal self-sampling is comparable with hrHPV clinician cervical sampling when using any triage strategy to refer women to colposcopy, so self-sampling is a viable cervical screening method. Therefore, policymakers should consider incorporating self-sampling into cervical screening programs to increase screening coverage and reduce cervical cancer burden.See related Spotlight, p. 649

  • Open Access

    Data from Clinical Performance of hrHPV Primary Screening Using Vaginal versus Cervical Samples to Detect High-grade Intraepithelial Lesions

    by Jonathan King, Yvonne N. Flores, Joacim Meneses-León, Sonia Hernández-Salazar, Karina Robles-Rivera, Berenice Rivera-Paredez, Leith León-Maldonado, Rubí Hernández-López, Leticia Torres-Ibarra, Eduardo Lazcano-Ponce, et al.

    High-risk human papillomavirus (hrHPV) testing is now the most recommended primary method for cervical cancer screening worldwide. Clinician-collected cervical sampling continues to be the main sampling method, but hrHPV vaginal self-sampling is an appealing alternative because of its greater acceptability and potentially higher cost-effectiveness. This study aimed to determine whether hrHPV vaginal self-sampling is comparable with clinician-collected cervical sampling for detecting histologically confirmed high-grade cervical intraepithelial neoplasia (CIN2/3) as part of a cervical cancer screening program in Mexico. We analyzed data from 5,856 women screened during a hrHPV-based screening study. Clinical performance and diagnostic efficiency metrics were estimated for the two sampling methods for the CIN3 and CIN2+ endpoints, using three triage strategies: HPV16/18 genotyping, HPV16/18/33/58 extended genotyping, and HPV16/18/31/33/58 extended genotyping. hrHPV-positivity was found in 801 (13.7%) cervical and 897 (15.3%) vaginal samples. All women with hrHPV-positive samples were referred to colposcopy, which detected 17 total CIN3 cases before considering retrospective triage strategies. Using the HPV16/18/31/33/58 extended genotyping strategy, 245 women had hrHPV-positive cervical samples and 269 had hrHPV-positive vaginal samples. Ten CIN3 cases were detected each among women with hrHPV-positive cervical samples and among those with hrHPV-positive vaginal samples when using this strategy, with no significant differences in sensitivity and specificity observed. We observe that self- and clinician-collected sampling methods are comparable for detecting CIN3 and CIN2+ regardless of the triage strategy used. These findings can help public health officials to develop more cost-effective cervical cancer screening programs that maximize participation.Prevention Relevance:We found that hrHPV vaginal self-sampling is comparable with hrHPV clinician cervical sampling when using any triage strategy to refer women to colposcopy, so self-sampling is a viable cervical screening method. Therefore, policymakers should consider incorporating self-sampling into cervical screening programs to increase screening coverage and reduce cervical cancer burden.See related Spotlight, p. 649

  • Clinical Performance of hrHPV Primary Screening Using Vaginal versus Cervical Samples to Detect High-grade Intraepithelial Lesions

    by Jonathan King, Yvonne N. Flores, Joacim Meneses-León, Sonia Hernández-Salazar, Karina Robles-Rivera, Berenice Rivera-Paredez, Leith León-Maldonado, Rubí Hernández-López, Leticia Torres-Ibarra, Eduardo Lazcano-Ponce, et al.

    High-risk human papillomavirus (hrHPV) testing is now the most recommended primary method for cervical cancer screening worldwide. Clinician-collected cervical sampling continues to be the main sampling method, but hrHPV vaginal self-sampling is an appealing alternative because of its greater acceptability and potentially higher cost-effectiveness. This study aimed to determine whether hrHPV vaginal self-sampling is comparable with clinician-collected cervical sampling for detecting histologically confirmed high-grade cervical intraepithelial neoplasia (CIN2/3) as part of a cervical cancer screening program in Mexico. We analyzed data from 5,856 women screened during a hrHPV-based screening study. Clinical performance and diagnostic efficiency metrics were estimated for the two sampling methods for the CIN3 and CIN2+ endpoints, using three triage strategies: HPV16/18 genotyping, HPV16/18/33/58 extended genotyping, and HPV16/18/31/33/58 extended genotyping. hrHPV-positivity was found in 801 (13.7%) cervical and 897 (15.3%) vaginal samples. All women with hrHPV-positive samples were referred to colposcopy, which detected 17 total CIN3 cases before considering retrospective triage strategies. Using the HPV16/18/31/33/58 extended genotyping strategy, 245 women had hrHPV-positive cervical samples and 269 had hrHPV-positive vaginal samples. Ten CIN3 cases were detected each among women with hrHPV-positive cervical samples and among those with hrHPV-positive vaginal samples when using this strategy, with no significant differences in sensitivity and specificity observed. We observe that self- and clinician-collected sampling methods are comparable for detecting CIN3 and CIN2+ regardless of the triage strategy used. These findings can help public health officials to develop more cost-effective cervical cancer screening programs that maximize participation. Prevention Relevance: We found that hrHPV vaginal self-sampling is comparable with hrHPV clinician cervical sampling when using any triage strategy to refer women to colposcopy, so self-sampling is a viable cervical screening method. Therefore, policymakers should consider incorporating self-sampling into cervical screening programs to increase screening coverage and reduce cervical cancer burden. See related Spotlight, p. 649


  • Open Access

    Total, Bioavailable, and Free 25-Hydroxyvitamin D Equally Associate with Adiposity Markers and Metabolic Traits in Mexican Adults

    by Berenice Rivera-Paredez, Alberto Hidalgo-Bravo, Guadalupe León-Reyes, Leith S. León-Maldonado, Arnoldo Aquino-Gálvez, Manuel Castillejos-López, Edgar Denova-Gutiérrez, Yvonne N. Flores, Jorge Salmerón, Rafael Velázquez-Cruz

    Epidemiological studies suggest a relationship between total 25-hydroxyvitamin D [25(OH)D], adiposity, and metabolic traits. The bioavailability of 25(OH)D is regulated by the albumin, vitamin D binding protein (VDBP), and variants of the GC gene. Therefore, it is not clear if bioavailable or free 25(OH)D offer additional benefits compared to total 25(OH)D when estimating the magnitude of these associations. Our aim was to evaluate the association between 25(OH)D (total, free and bioavailable) with adiposity and metabolic traits. This was a cross-sectional study of 1904 subjects from the Health Workers Cohort Study from Mexico. Free and bioavailable 25(OH)D were calculated based on VDBP and albumin determinations, using a formula adjusted for the GC gene diplotypes. Adiposity and metabolic traits were measured with standardized procedures. Free and bioavailable 25(OH)D levels correlated with total 25(OH)D, r = 0.71 and 0.70, respectively (p < 0.001). Total, bioavailable and free 25(OH)D levels were negatively associated with the adiposity marker (visceral adiposity index) and metabolic traits (metabolic syndrome, type 2 diabetes, triglycerides, triglycerides/HDL-c ratio, and triglycerides/glucose index) in multivariate regression models (ORs = 0.73 to 0.96). Our findings suggest that free and bioavailable 25(OH)D do not offer additional advantages over total 25(OH)D regarding its association with adiposity and several metabolic traits in Mexican adults.


  • Open Access

    Performance of an affordable urine self-sampling method for human papillomavirus detection in Mexican women

    by Rubí Hernández-López, Luis Hermosillo, Leith León-Maldonado, Rafael Velázquez-Cruz, Leticia Torres-Ibarra, Eduardo Lazcano-Ponce, Attila Lörincz, Cosette M Wheeler, F Xavier Bosch, Jack Cuzick, et al.

    Introduction: Urine self-sampling for human papillomavirus (HPV)-based cervical cancer screening is a non-invasive method that offers several logistical advantages and high acceptability, reducing barriers related to low screening coverage. This study developed and evaluated the performance of a low-cost urine self-sampling method for HPV-testing and explored the acceptability and feasibility of potential implementation of this alternative in routine screening. Methods: A series of sequential laboratory assays examined the impact of several pre-analytical conditions for obtaining DNA from urine and subsequent HPV detection. Initially, we assessed the effect of ethylaminediaminetetraacetic acid (EDTA) as a DNA preservative examining several variables including EDTA concentration, specimen storage temperature, time between urine collection and DNA extraction, and first-morning micturition versus convenience sample collection. We further evaluated the agreement of HPV-testing between urine and clinician-collected cervical samples among 95 women. Finally, we explored the costs of self-sampling supplies as well as the acceptability and feasibility of urine self-sampling among women and healthcare workers. Results: Our results revealed higher DNA concentrations were obtained when using a 40mM EDTA solution, storing specimens at 25°C and extracting DNA within 72 hrs. of urine collection, regardless of using first-morning micturition or a convenience sampling. We observed good agreement (Kappa = 0.72) between urine and clinician-collected cervical samples for HPV detection. Furthermore, urine self-sampling was an affordable method (USD 1.10), well accepted among cervical cancer screening users, healthcare workers, and decision-makers. Conclusion: These results suggest urine self-sampling is feasible and appropriate alternative for HPV-testing in HPV-based screening programs in lower-resource contexts.


  • Adjunctive testing by cytology, p16/Ki‐67 dual‐stained cytology or HPV16/18 E6 oncoprotein for the management of HPV16/18 screen‐positive women

    by Leticia Torres‐Ibarra, Attila T. Lorincz, Cosette M. Wheeler, Jack Cuzick, Rubí Hernández‐López, Donna Spiegelman, Leith León‐Maldonado, Berenice Rivera‐Paredez, Pablo Méndez‐Hernández, Eduardo Lazcano‐Ponce, et al.

    High‐risk human papillomavirus type 16/18 (HPV16/18) genotyping is unable to accurately discriminate nonprogressive infections from those that will progress to cervical cancer. Our study aimed to assesses if additional testing either with liquid‐based cytology (LBC) or the putative progression markers p16/Ki‐67 and HPV16/18 E6 oncoprotein (E6) can improve the efficiency of HPV16/18 genotyping for triaging high‐risk HPV (hrHPV)‐positive women through better cancer risk stratification. Women attending colposcopy after positive HPV16/18 genotyping results within the Forwarding Research for Improved Detection and Access for Cervical Cancer Screening and Triage (FRIDA) hrHPV‐based screening study in Tlaxcala, Mexico, underwent further testing with LBC, p16/Ki‐67 dual‐stained (DS) cytology and E6. We calculated measures of test performance for detecting histologically confirmed cervical intraepithelial neoplasia grade 2 or higher (CIN2+) and grade 3 or higher (CIN3+). A number of 475 (64.3%) of 739 HPV16/18‐positive women had complete results for all tests. Triage positivity rates were 14.1%, 18.5% and 24.4%, for LBC, E6 and DS, respectively. Compared with LBC, DS had higher sensitivity (24.4% vs 60.0%) although lower specificity (87.0% vs 79.3%) for CIN3+ (P < .001), whereas E6 had a sensitivity of 37.8% and a specificity of 83.5%. No invasive cancer was missed by DS or E6, but 75% were in normal cytology. DS test was associated with nearly 75% reduction of colposcopy referrals compared with the direct referral of all HPV16/18‐positive women, giving the least number of colposcopies (n = 4.3) per CIN3+ detected. We show that adjunctive testing of HPV16/18‐positive women with DS may greatly reduce unnecessary colposcopy referrals within HPV‐based screening employing HPV16/18 genotyping while retaining acceptable sensitivity for CIN2+ and CIN3+.


  • Open Access

    Cumulative soft drink consumption is associated with insulin resistance in Mexican adults

    by Berenice Rivera-Paredez, Leticia Torres-Ibarra, Romina González-Morales, Tonatiuh Barrientos-Gutiérrez, Rubí Hernández-López, Paula Ramírez, Leith León-Maldonado, Rafael Velázquez-Cruz, Edgar Denova-Gutiérrez, Jorge Salmerón

    Insulin resistance (IR) is an important risk factor for type 2 diabetes (T2D) and other cardiometabolic diseases. Recent studies suggest that soft drink consumption could increase IR. However, inconsistent findings have been observed. The aim was to estimate the association between the cumulative consumption of soft drinks and IR by means of the HOMA-IR in Mexican adults. We analyzed the association between cumulative consumption of soft drinks and HOMA-IR change after 7 y of follow-up in participants (n = 1073) of the Health Workers Cohort Study. Soft drink consumption was estimated by food-frequency questionnaires. Insulin was measured by chemiluminescence, and fasting glucose was measured with the enzymatic colorimetric method. HOMA-IR was computed as fasting insulin (mIU/L) × fasting glucose (mmol/L)/22.5. To assess the relation between cumulative soft drink consumption and HOMA-IR change, we performed robust linear regression models. Additionally, we used fixed-effects models to estimate the association between changes in soft drink consumption and change in HOMA-IR. At baseline, the average age was 44 y. Mean cumulative soft drink consumption was 0.42 servings/d. Median HOMA-IR increased from 1.5 at baseline to 2.0 at follow-up. Soft drink consumption was positively associated with HOMA-IR change. In the multiple linear regression analysis, for each increase in the consumption of 2 (355 mL) soft drinks/d, the average change between baseline and follow-up HOMA-IR showed an increase of 1.11 units (95% CI: 0.74, 1.48). Our data support the hypothesis that, in Mexican adults, a higher soft drink consumption is associated with an increase in HOMA-IR, despite known risk factors. These findings support the need for reinforcing policies to reduce soft drink consumption in our population.